{"nctId":"NCT00898677","briefTitle":"Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)","startDateStruct":{"date":"1995-09"},"conditions":["Migraine Headache"],"count":1268,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: sumatriptan"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"rizatriptan benzoate","otherNames":["rizatriptan","MK0462"]},{"name":"rizatriptan benzoate","otherNames":["rizatriptan","MK0462"]},{"name":"Comparator: sumatriptan","otherNames":["sumatriptan"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient had at least a 6-month history of migraine, with or without aura\n* Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions.\n* Patient was judged to be in good health, apart from migraine\n\nExclusion Criteria:\n\n* Patient was pregnant or a nursing mother\n* Patient had abused drugs or alcohol within 12 months prior to entering the study\n* Patient had a history of cardiovascular disease\n* Patient had clinically significant Electrocardiography (ECG) abnormality\n* Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening\n* Patient received treatment with an investigational device or compound within 30 days of the study start\n* Patient typically suffered from less then 1 or more than 8 attacks of migraine per month\n* Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches\n* Patient had hypersensitivity to sumatriptan\n* Patient had participated in any previous study involving rizatriptan","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Relief at 2 Hours After Dose","description":"Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"258","spread":null},{"groupId":"OG002","value":"239","spread":null},{"groupId":"OG003","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"127","spread":null},{"groupId":"OG002","value":"148","spread":null},{"groupId":"OG003","value":"95","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Relief Within 2 Hours After Dose","description":"Patients reporting time to relief defined as the first time point at which a patient reported headache severity grade 1 or 0 (mild pain or no headache) within 2 hours after dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"265","spread":null},{"groupId":"OG002","value":"247","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"140","spread":null},{"groupId":"OG003","value":"87","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Free at 2 Hours After Dose","description":"Patients pain free (defined as a reduction of headache severity to grade 0 \\[no pain\\]) at 2 hours after treatment. Each patient rated headache severity on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"155","spread":null},{"groupId":"OG002","value":"127","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"230","spread":null},{"groupId":"OG002","value":"260","spread":null},{"groupId":"OG003","value":"139","spread":null}]}]}]},{"type":"SECONDARY","title":"Functional Status at 2 Hours After Dose","description":"Patients with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each patient rated functional disability on a 4-grade scale (0 = no functional disability; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 = unable to carry out daily activities, requires bed rest).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"160","spread":null},{"groupId":"OG002","value":"126","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"142","spread":null},{"groupId":"OG003","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"67","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Nausea at 2 Hours After Dose","description":"Patients who recorded the presence or absence of nausea 2 hours after dose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"128","spread":null},{"groupId":"OG003","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"290","spread":null},{"groupId":"OG002","value":"259","spread":null},{"groupId":"OG003","value":"91","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":164},"commonTop":["Somnolence","Dizziness","Asthenia/Fatigue","Nausea","Pain, Abdominal"]}}}